J&J Precise Panel Vote Nearly Split On Carotid Disease Subgroup Benefit
This article was originally published in The Gray Sheet
Executive Summary
Carotid revascularization with Cordis' Precise stent is a safe alternative to surgery for high-risk patients, although its benefit to asymptomatic patients remains unclear, an FDA panel concluded April 21
You may also be interested in...
Blues TEC Assessment Less Enthusiastic About Carotid Stents Than CMS
Existing data on carotid stenting with distal embolic protection fail to demonstrate that the procedure produces better outcomes than surgery, BlueCross BlueShield Association's Technology Evaluation Center concluded Feb. 10
Blues TEC Assessment Less Enthusiastic About Carotid Stents Than CMS
Existing data on carotid stenting with distal embolic protection fail to demonstrate that the procedure produces better outcomes than surgery, BlueCross BlueShield Association's Technology Evaluation Center concluded Feb. 10
SAPPHIRE Held Up To The Light: Surgeons Reflect On Carotid Stent Data
FDA panelist Anthony Comerota, MD, is challenging carotid stent proponents to prove the technology's superiority over endarterectomy in a more relevant patient group than Johnson & Johnson/Cordis' SAPPHIRE trial enrolled